thyssenkrupp nucera AG & Co. KGaA
thyssenkrupp nucera confirms outlook for fiscal year 2023/24 – Expectations for AWE business in fiscal year 2024/25 not sustained – Earnings in third quarter of 2023/24 above expectations

thyssenkrupp nucera confirms outlook for fiscal year 2023/24 – Expectations for the AWE business in fiscal year 2024/25 not sustained – Earnings in the third quarter of 2023/24 above expectations

• thyssenkrupp nucera AG & Co. KGaA (“thyssenkrupp nucera”) confirms its sales and earnings outlook for the current financial year based on preliminary and unaudited figures for the third quarter of 2023/24. At Group level, sales of EUR 820 million to EUR 900 million (2022/23: EUR 653 million) and EBIT in the negative mid-double-digit million euro range (2022/23: EUR 24 million) are still expected. The sales outlook for the alkaline water electrolysis (AWE) business of between EUR 500 million and EUR 550 million for the 2023/24 financial year is also confirmed.
• For the upcoming financial year 2024/25, the previously communicated sales and earnings expectations for the alkaline water electrolysis business is not being sustained. This is primarily due to the ongoing uncertainties in the market, which have led to further delays in new projects on the customer side and make a reliable outlook for the 2024/25 financial year impossible at the present time. thyssenkrupp nucera assumes that these delays will not affect the long-term development prospects.
• The preliminary, unaudited figures for the third quarter of 2023/24 are above market expectations: thyssenkrupp nucera increased sales at Group level by 26% to EUR 236 million (Q3 2022/23: EUR 188 million). EBIT fell by just EUR 6 million year-on-year to EUR 1 million in the third quarter of 2023/24 (Q3 2022/23: EUR 7 million).
• The results of the third quarter will be published on August 13, 2024. thyssenkrupp nucera will publish its outlook for the 2024/25 financial year as planned with the publication of the annual results for the 2023/24 financial year.